Accuryn Medical develops a monitoring system aimed at enhancing the detection and prevention of acute kidney injury during critical care.

Accuryn Medical

Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was incorporated in 1977 and is headquartered in Cupertino, California.

Ron Wayne

Steve Jobs

Steve Wozniak

Apple Inc.

BioPharma Trend is a platform that provides news, insights, and information about the biopharmaceutical industry.

BioPharma Trend

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earl Bakken

Alfred E. Mann

Daniel Grossman

Palmer Hermundslie

Medtronic plc

Accuryn Medical | 10,415 followers on LinkedIn. We are a predictive health company on a mission to help physicians predict acute kidney injury before it happens. | Accuryn Medical is a predictive health company that is developing the next generation of smart sensors and artificial intelligence.

Currently, Accuryn Medical is developing a predictive health platform to help medical teams better predict adverse outcomes in critical care settings. The Accuryn® Monitoring System is not cleared for prediction of disease states or clinical conditions.

Brian Magee

Praveena Mallarkandy

Chief Product Officer at Accuryn Medical

Rich Keenan

VP Marketing

Myria Crawford

Stronger than ever! As we enter this new year, we are excited to continue our growth as a company and strengthen our ability to serve the clinicians and patients who rely on Accuryn every day. Today, we are celebrating 3 milestones. 1) Our restructuring is complete with an equity offering that was over-subscribed at the close! 2) We are now lead by a new Board of Directors who share our passion for helping clinicians reduce the impact of hospital acquired AKI. 3) The company will be known simply as Accuryn Medical going forward in alignment with our singular focus on kidney care. So what's next? More patients treated every day: ~70,000 patients have experienced the benefits of Accuryn and this number continues to grow daily. Software Updates: We have recently launched several upgrades to complement Accuryn’s proprietary Active Drain Line technology. Noteworthy is AKI Detect software which detects oliguric Acute Kidney Injury (AKI) in accordance with KDIGO guidelines Expanded Offering: More patients will be able to experience the benefits of Accuryn as we launch TEN new catheter sizes; all designed to reduce the risks associated with CAUTI. Stay Tuned for more announcements coming soon! #protectthekidney #criticalcare #aki #surgeons #nurses

The journey to improving patient outcomes begins with knowledge. Catch the replay of Alice B. 's webinar on the critical role of AKI management in ICU care and learn practical strategies for real-time kidney monitoring. Watch now: https://lnkd.in/dCegdRWb #AKI #Nurses #CriticalCare #AskNurseAlice

Cardiac surgery places significant demands on the body, and fluid imbalances often complicate recovery. With Accuryn’s real-time monitoring, cardiac teams can manage fluid levels with accuracy, reducing the likelihood of acute kidney injury and other post-op risks. Accuryn’s technology empowers clinicians to prioritize kidney health, ultimately improving patient outcomes. Experience how this technology can support your team—book a demo: https://lnkd.in/gAfFp5-i #aki #criticalcare #protectthekidney

Missed our live session? The replay of “The Many Faces of Acute Kidney Injury” with Alice B. is now available! Learn essential insights into AKI management and see how proactive care can make a difference in critical care settings. Watch now: https://lnkd.in/dCegdRWb #AKI #ProtectTheKidney #CriticalCare

In critical care, accurate urine output plays a vital role in fluid balance, especially in cases like trauma or post-surgery. Real-time monitoring is key in detecting kidney injury (AKI) and supporting patient recovery. #protectthekidney #criticalcare #aki #surgeons #nurses

AKI is one of the most common complications in ICU patients. Monitoring kidney function continuously helps detect early signs, ensuring timely intervention. #protectthekidney #criticalcare #aki

Want to Improve Patient Care? Here’s a Game-Changer. How to make a real impact on patient care without overwhelming your nursing team? It turns out the secret lies in simplifying monitoring processes and using the right tools. Accuryn’s advanced monitoring system is designed to automate urine output tracking, reduce CAUTI risks, and detect AKI up to 33 hours earlier than traditional methods. This means less time spent on manual tasks and more time for nurses to focus on what matters most—patient care. The result? Hospitals using Accuryn have reported significant improvements in both efficiency and outcomes.

🔴 Webinar Alert: The Many Faces of Acute Kidney Injury Did you know that nearly a third of ICU patients are at risk of developing Acute Kidney Injury (AKI), often without clear signs? In the rush of critical care, key indicators like urine output or fluid volume shifts can easily go unnoticed, yet they hold vital clues to early AKI detection. Are we missing essential markers that could make all the difference? 🧐 Leaders like Alice B. know this (and thankfully educate the public on it!) AKI can lead to serious complications, including sepsis or dialysis. With the right insights, early intervention is possible. Join Clinical Nurse Specialist Barbara McLean as we discuss the subtle signs, lab changes, and proactive strategies that can make an impact on patient care. 🗓 Date: November 7, 2024 ⏰ Time: 3:00 PM EST 📍 Virtual Event 📲 Tune in live or catch the replay! Register now: https://lnkd.in/dCegdRWb #protectthekidney #criticalcare #nurses #aki #kidneyinjury #kidneyhealth #icu

Check out this new article: https://lnkd.in/gc8tectb

Think You Can’t Save Time on Foley Catheter Management? Think Again—Here’s the Proof! .... Lisette Wannemacher, RN, BSN, CPN, shares her team’s experience with the Accuryn Monitoring System. See how its automation, including Active Drain Line Clearance, has transformed their Foley catheter management process. https://lnkd.in/gmBM5b5Q

Metric
Company Name	Accuryn Medical	Apple Inc.	BioPharma Trend	Medtronic plc
Symbol		AAPL		MDT
MSH ID	COM:ACCURYN	COM:APPLE	COM:BIOPHARMATREND	COM:MEDTRONIC
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Technology	Healthcare & Health Services	Healthcare
Industry	Medical Devices	Consumer Electronics	Biopharmaceutical Information Services	Medical - Devices
Country	US	US	US	IE
Stage
Employee Count		150K		95K
Website	accuryn.com	apple.com	biopharmatrend.com	medtronic.com
LinkedIn	accuryn-medical	apple
Founders

Metric
Market Cap		3.57T	98.81B
Enterprise Value
Monthly Web Traffic	3.98K	863.88M	2.66M
Web Traffic Growth	0.28	0.17	0.29
Valuation
Raised Capital

Metric
Revenue	391.04B	32.36B
Revenue (LTM)
Revenue (NTM)
Gross Profit	180.68B	19.45B
EBITDA	134.66B	8.38B
Operating Income	123.22B	5.73B
Net Income	93.74B	3.68B
EPS	6.11	2.77
Diluted EPS	6.08	2.76
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.46	0.66
Operating Profit Margin	0.31	0.18
EBITDA Margin	0.34	0.26
Net Profit Margin	0.26	0.13
Return on Equity	1.56	0.08
Return on Assets	0.31	0.05
Return on Capital Employed	0.60	0.07

ACCU

COM:ACCURYN

Accuryn Medical

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	28.89	28.22
P/B Ratio	39.34	2.25
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.44	3.63
EV Multiple	27.24	12.19

Metric
Days Sales Outstanding	21.95	67.78
Days Payables Outstanding	100.09	71.76
Days Inventory Outstanding	11.21	187.43
Operating Cycle	58.62	254.83
Cash Conversion Cycle	-30.11	189.62
Asset Turnover	1.16	0.36

Metric
Operating Cash Flow	118.25B	6.79B
Free Cash Flow	118.25B	5.20B
Cash Flow to Debt	1.12	0.27
Operating Cash Flow/Sales	0.30	0.21
Free Cash Flow Yield	0.04	0.03

Metric
Cash & Equivalents	29.94B	1.28B
Accounts Receivable	-3.79B	-391M
Inventory	7.29B	5.22B
Goodwill		40.99B
Debt to Capitalization	0.60	0.37
Debt to Assets	0.27	0.28
Current Ratio	1.07	2.29
Quick Ratio	0.99	1.61

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03	0.01
R&D to Revenue	0.08	0.08
SG&A to Revenue